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Introduction: Several scoring systems have been developed to predict postoperative mortality and complications
in patients undergoing cardiac surgery. However, these computer-based calculations are time- and cost-intensive. A
simple but highly predictive test for postoperative risk would be of clinical benefit with respect to increasingly
scarce hospital resources. We therefore assessed the predictive power of fibroblast growth factor 23 (FGF23)
measurement compared with an established scoring system.
Methods: We conducted a prospective interdisciplinary observational study at the Saarland University Medical
Centre that included 859 patients undergoing elective cardiac surgery between January 2010 and March 2011 with
a median follow-up after discharge of 822 days. We compared a single preoperative measurement of FGF23 as a
prognostic tool with the 18 parameters comprising EuroSCORE II with respect to postoperative mortality, acute
kidney injury, non-occlusive mesenteric ischemia, clinical course and long-term outcome.
Results: Preoperative FGF23 levels were highly predictive of postoperative outcome and complications. The
predictive value of FGF23 for mortality in the receiver operating characteristic curve was greater than the
EuroSCORE II (area under the curve: 0.800 versus 0.725). Moreover, preoperative FGF23 independently predicted
postoperative acute kidney injury and non-occlusive mesenteric ischemia comparably to the EuroSCORE II. Finally,
FGF23 was found to be an independent predictor of clinical course parameters, including duration of surgery,
ventilation time and length of stay.
Conclusions: In patients undergoing elective cardiac surgery, a simple preoperative FGF23 measurement is a
powerful indicator of surgical mortality, postoperative complications and long-term outcome. Its utility compares to
the widely used EuroSCORE II.Introduction
An increasingly elderly population has resulted in greater
cardiovascular disease prevalence and an associated need
for cardiac surgery [1,2]. Despite several studies demon-
strating improved survival and quality of life data in eld-
erly patients undergoing cardiac surgery, non-elective* Correspondence: matthias.klingele@uks.eu
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unless otherwise stated.surgery is associated with a two to three times greater risk
of death [3-5]. Even though risk of perioperative morbidity
is greater in these patients, age does not represent an ab-
solute contraindication for surgical intervention, with pa-
tient selection remaining the ultimate predictor of clinical
outcome [5]. In order to assess the risk of patient mortal-
ity prior to cardiac surgery, scoring systems have been de-
veloped that incorporate risk factors such as age [6,7]. The
EuroSCORE II is a widely used and well-established
scoring system comprising 18 distinct variables. How-
ever, to date, simple preoperative prognostic biomarkers
have remained unavailable.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Speer et al. Critical Care  (2015) 19:190 Page 2 of 10Fibroblast growth factor 23 (FGF23) has recently
emerged as a powerful biomarker for adverse outcome
in patients with or without chronic kidney disease
(CKD) [8,9]. The hormone FGF23 is secreted by osteo-
blasts [10], resulting in increased phosphate excretion
[11] and decreased renal 1α-hydroxylation of 25-OH
vitamin D [12,13]. FGF23 levels begin to rise early within
the course of CKD [14]. Although the precise physio-
logical mechanism remains uncertain, phosphate accu-
mulation due to impaired renal function is thought to
induce secretion of FGF23, thereby increasing renal
phosphate excretion and maintaining serum phosphate
levels within a physiological range. In spite of this, ele-
vated FGF23 levels are associated with worse clinical
outcomes in patients with CKD [15-17]. Interestingly, an
association between FGF23 levels, impaired left ventricu-
lar (LV) function and atrial fibrillation has been reported
in patients with CKD and even in patients without renal
failure [18,19]. Furthermore, FGF23 predicts risk of
cardiovascular mortality and progression to congestive
cardiac failure in patients with stable coronary artery
disease [9].
The effect of FGF23 on its physiological target organs
(that is, the kidneys and the parathyroid glands) depends
on its co-receptor α-Klotho. The Klotho gene has a role
within the aging process, and different FGF-Klotho co-
receptors exist within the human body [20].
In the present study, we evaluated the predictive
power of a preoperative FGF23 measurement as a bio-
marker of postoperative complications, clinical course
and in-hospital mortality, as well as of long-term out-
come after hospital discharge, in patients undergoing
elective cardiac surgery.
Materials and methods
Study design and setting
From January 2010 to March 2011, all patients sched-
uled for elective cardiac surgery within the Department
of Thoracic and Cardiovascular Surgery at the Saarland
University Medical Centre in Germany were screened
for inclusion. Exclusion criteria included age <18 years,
refusal to participate, emergency admissions for cardiac
surgery, haemodynamic instability necessitating emer-
gency cardiac surgery, or inability to give written con-
sent for participation. The study was designed as a
prospective cohort study and was approved by the local
ethics committee (Landesärztekammer des Saarlandes
reference ID 199/09). Written informed consent was ob-
tained from all patients included in this study.
Clinical data were obtained during an initial patient
interview and subsequent review of medical documenta-
tion. Patient demographic and perioperative data were
entered into a databank. Patients were characterised ac-
cording to smoking status with respect to calculatedtotal pack-year history. Patients with current use of anti-
diabetic medications, repeated blood glucose levels
>250 mg/dl or haemoglobin A1c levels >7% were cate-
gorised as having diabetes mellitus. Arterial angiography
was performed in patients with suspected non-occlusive
mesenteric ischaemia (NOMI) after the surgical proced-
ure [21], with the diagnosis made according to the vas-
cular scoring system described by Minko et al. [22].
Postoperative acute kidney injury (AKI) was defined on
the basis of Acute Kidney Injury Network (AKIN) cri-
teria [23] (that is, an AKIN score ≥1).
Observation period after discharge
Each participant had a follow-up telephone interview be-
tween October 2012 and December 2012, corresponding
to 2 to 3 years after hospital discharge. The following
data were collected: date of death (if applicable), cause
of death, myocardial infarction, angina pectoris with
consecutive hospital admission, percutaneous translumi-
nal coronary angioplasty and/or stenting, coronary artery
bypass graft, resuscitation, hospitalization due to heart
failure, stroke, initiation of renal replacement therapy,
New York Heart Association stage and intake of di-
uretics. In case of mortality, a family member was con-
tacted. When neither the patient nor a relative could be
contacted, the general practitioner, cardiologist or neph-
rologist to whom a letter of discharge had been sent was
contacted. In cases where this was unsuccessful, the
registry office was questioned if the patient had died.
Laboratory parameters and measurements
Blood samples for biochemical monitoring were proc-
essed in the central laboratory of the Saarland University
Medical Centre. Blood samples were obtained under
standard conditions alongside routine preoperative la-
boratory assessment within 24 hours prior to surgery
and centrifuged at 2,800 × g for 10 minutes at 4°C. Su-
pernatants were stored in aliquots at −80°C. C-terminal
FGF23 levels were measured from plasma samples by
enzyme-linked immunosorbent assay (lowest cutoff value
of 3 relative units (RU)/ml, highest cutoff value of 2,000
RU/ml; Immutopics International, San Clemente, CA,
USA). The results are reported as relative units, whereby 1
RU/ml equates to 2 pg/ml according to the manufacturer’s
guidelines.
Patients were categorised into tertiles according to
FGF23 level, allowing assessment of risk for the end-
points death, kidney failure, NOMI and long-term mor-
tality through comparison of three clinically simple
categories: low, medium and high risk.
EuroSCORE II
To predict early mortality after cardiac surgery, a scoring
system was developed based on a panel of risk factors
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creased significantly over the last 15 years, the former
EuroSCORE I has been superseded by EuroSCORE II,
which incorporates 18 factors proven to influence risk
[6]. All patients were preoperatively categorised accord-
ing to their EuroSCORE II.
Statistical analysis
Continuous variables are expressed as mean ± standard de-
viation (normally distributed variables) or as median and
interquartile range (IQR) (skewed variables). Categorical
variables are presented as a percentage unless otherwise
stated. For comparisons between continuous variables, the
Kruskal-Wallis H test was used. Categorical variables were
compared by use of the χ2 test or Fisher’s exact test. The
association between continuous variables was assessed by
Spearman’s rank correlation testing.
To examine the association between FGF23 and AKI
as well as NOMI during hospitalisation, binary logistic
regression analyses were performed, including FGF23 di-
vided into tertiles as a categorical variable. Moreover,
additional models were calculated, adjusting for poten-
tial confounders (age, sex, mean arterial blood pressure,
sinus rhythm, coronary artery disease, chronic heart fail-
ure, diabetes, serum creatinine and serum high-sensitivity
C-reactive protein (hsCRP)). An additional model was
built, adjusting for EuroSCORE II, comprising 18 variables
as described above. Furthermore, linear regression ana-
lyses were used to determine the association between log-
transformed FGF23 as a continuous variable and different
metric variables during hospitalisation (duration of sur-
gery and cardiopulmonary bypass, time of hypothermic
circulatory arrest, ventilation time, length of stay on the
intensive care unit (ICU), and length of in-hospital stay).
Finally, to assess the effect of increasing serum FGF23
level on mortality during follow-up, Cox regression ana-
lyses were performed using FGF23 stratified into tertiles
and adjusted for age, sex, mean arterial blood pressure,
sinus rhythm, coronary artery disease, chronic heart fail-
ure, diabetes, serum creatinine and serum hsCRP. Similar
calculations were performed for the N-terminal fragment
of the prohormone B-type brain natriuretic peptide (NT-
proBNP) divided into tertiles or using log-transformed
NT-proBNP. Additionally, Kaplan-Meier survival plots
were used to examine the relationship between tertiles of
FGF23 and mortality after discharge. For binary logistic
regression analyses, c-statistics are reported.
To compare the power of FGF23 and EuroSCORE II
in predicting mortality and the occurrence of AKI and
NOMI, receiver operating characteristic (ROC) curve
analyses were performed, with the area under the curve
(AUC) reported for each parameter. Statistical differ-
ences between the AUC under two different ROC curves
were examined by using the Hanley-McNeil test.Two-sided P-values <0.05 were considered statistically
significant. All statistical analyses were carried out using
SPSS 20.0 software (IBM, Armonk, NY, USA).
Results
Participants and descriptive data
A total of 1,163 patients underwent elective cardiac sur-
gery with extracorporeal circulation within our centre
during the screening period. Among these, 865 patients
met the study inclusion criteria. Six patients were subse-
quently excluded from analysis for lack of blood samples
for measurement of FGF23. The remaining 859 patients
were divided into 3 groups according to preoperative
FGF23 level. The patients’ baseline characteristics are pre-
sented in Table 1. The patients’ mean age (with standard
deviation (SD)) was 63.7 ± 1.46 years, and 68.6% of partici-
pants were male. The patients in the highest FGF23 tertile
were more likely to be older, female or have preexisting
diabetes. Indications for cardiac surgery and LV ejection
fraction were comparable between tertiles. However, me-
dian pro-BNP was six times higher in patients in the high-
est FGF23 tertile than among those in the lowest tertile.
Moreover, patients with endocarditis and patients requir-
ing resternotomy had significantly higher FGF23 serum
concentrations (data not shown).
Preoperative FGF23 level as predictor of postoperative
mortality
Total in-hospital mortality was 2.9% (that is, half that
predicted by EuroSCORE II). FGF23No inpatient mor-
tality was noted in the lowest FGF23 tertile, compared
with 2.1% and 6.7% mortality in the other two tertiles.
According to EuroSCORE II, predictive mortality was
4.0%, 6.0% and 8.0% in the lowest to highest tertiles, re-
spectively. ROC curve analysis for FGF23, EuroSCORE
II and NT-proBNP for prediction of surgical mortality is
presented in Figure 1. The predictive value of preoperative
FGF23 level was comparable to that of the EuroSCORE II
(AUC: 0.800 versus 0.725; P = 0.172) and even higher than
NT-proBNP (AUC: 0.740).
Preoperative FGF23 level as predictor of outcome after
hospital discharge
A significant association was noted between preoperative
FGF23 level and mortality during the long-term observa-
tion period after hospital discharge (Figure 2). During a
median follow-up period of 822 (IQR: 359 to 1,071)
days, mortality was 4.47 times higher in patients in the
highest FGF23 tertile than in the lowest tertile (Table 2).
Even after adjustment for age, sex, mean arterial blood
pressure, sinus rhythm, coronary artery disease, chronic
heart failure, diabetes, and serum creatinine and hsCRP
levels, mortality remained 2.34 times higher in patients
within the highest FGF23 tertile than in the lowest tertile
Table 1 Baseline characteristics of study participantsa










Male sex (%) 80.8 69.9 54.9 68.6 <0.001
Age (yr) 59.1 ± 14.9 63.7 ± 14.3 68.3 ± 13.2 63.7 ± 1.46 <0.001
Indication for cardiac surgeryc
Valvulopathy (%) 72.5 69.2 68.7 70.1 0.561
Coronary artery disease (%) 34.5 40.9 37.7 37.7 0.285
Aortic disease (%) 35.2 28.0 23.2 28.8 0.006
Mean arterial blood pressure (mmHg) 94 ± 30 90 ± 36 82 ± 38 89 ± 35 <0.001
Sinus rhythm (%) 92.3 84.6 76.8 84.6 <0.001
Diabetes mellitus (%) 14.6 26.1 35.4 24.8 <0.001
Coronary artery disease (%) 36.2 45.5 47.2 42.9 0.018
Chronic cardiac failure (%) 90.2 85.7 83.1 86.3 0.042
Ejection fraction (%) 50 ± 27 49 ± 25 48 ± 26 49 ± 26 0.542
EuroSCORE II 2.6 (1.4 to 5.2) 3.7 (2.0 to 6.8) 5.7 (2.7 to 12.4) 3.8 (1.9 to 7.4) <0.001
FGF23 (RU/ml) 39.2 (31.7 to 45.4) 64.5 (56.5 to 75.3) 182.9 (114.5 to 416.5) 64.5 (45.4 to 114.5) <0.001
Serum creatinine (mg/dl) 0.98 ± 0.20 1.06 ± 0.26 1.53 ± 1.35 1.19 ± 0.84 <0.001
Serum NT-proBNP (pg/ml) 212 (90 to 612) 572 (170 to 1,415) 1,276 (443 to 3,575) 525 (156 to 1,507) <0.001
Serum hsCRP (mg/L) 1.6 (0.7 to 4.5) 2.4 (0.9 to 6.1) 5.2 (2.1 to 16.3) 2.6 (1.0 to 8.1) <0.001
Duration of surgery (min) 156 ± 43 171 ± 55 185 ± 67 171 ± 57 <0.001
Duration of cardiopulmonary bypass (min) 75 ± 32 80 ± 36 92 ± 48 82 ± 40 <0.001
Time of hypothermic circulatory arrest (min) 51 ± 22 51 ± 24 58 ± 34 53 ± 27 0.001
Ventilation time (hr) 9 (8 to 13) 11 (8 to 16) 14 (10 to 29) 11 (8 to 18) <0.001
Length of ICU stay (days) 1 (1 to 1) 1 (1 to 1) 1 (1 to 3) 1 (1 to 2) <0.001
Total length of stay (days) 9 (8 to 11) 10 (9 to 12) 11 (9 to 16) 10 (8 to 13) <0.001
Acute kidney injury (%) 11.8 23.1 45.8 26.8 <0.001
Non-occlusive mesenteric ischaemia (%) 3.8 6.6 16.5 9.0 <0.001
Death during hospitalisation (%) 0.0 2.1 6.7 2.9 <0.001
Death during follow-up (%) 3.1 5.6 12.2 7.0 <0.001
aFGF23, Fibroblast growth factor 23; hsCRP, High-sensitivity C-reactive protein; ICU, Intensive care unit; NT-proBNP, N-terminal fragment of the prohormone B-type
brain natriuretic peptide; RU, Relative units. Values are presented as mean ± standard deviation, median (interquartile range) or percentage where appropriate.
bP-value for the comparison between groups according to tertiles of FGF23. cMultiple indications are possible.
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or EuroSCORE II. In contrast, NT-proBNP did not sig-
nificantly predict mortality after hospital discharge
(Additional file 1).
Preoperative FGF23 level as predictor of postoperative
complications and clinical course
The incidence of postoperative complications such as AKI
differed significantly between patients in different FGF23
tertiles. Patients in the highest FGF23 tertile had a six
times higher likelihood of developing AKI after cardiac sur-
gery compared with those in the lowest tertile. Moreover,
preoperative FGF23 level was a significant and independ-
ent predictor of occurrence of postoperative AKI (Table 2).The likelihood of NOMI after cardiac surgery was 4.8
times higher in patients in the highest FGF23 tertile com-
pared with patients in the lowest tertile. Even after adjust-
ment for confounding variables, preoperative FGF23 level
remained an independent risk factor for NOMI (Table 2).
In similar models, patients in the highest tertile of
NT-proBNP had a significantly elevated risk for postop-
erative AKI (P = 0.001). However, we could not reveal a
significant association between NT-proBNP and the oc-
currence of NOMI (Additional file 1).
The predictive value of FGF23 and EuroSCORE II for
AKI was comparable, with AUC values of 0.715 and 0.719
(P = 0.892), respectively (Additional file 2). Interestingly,
even the predictive value of FGF23 and EuroSCORE II for
Figure 1 Receiver operating characteristic curve analyses of the
prediction of in-hospital mortality. AUC, Area under the curve;
FGF23, Fibroblast growth factor 23; NT-proBNP, N-terminal fragment
of the prohormone B-type brain natriuretic peptide FGF23.
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respectively; P = 0.838).
The preoperative FGF23 level was independently associ-
ated with duration of surgical procedure and postoperative
cardiorespiratory support, as well as with parameters of
overall clinical course, such as ventilation time, length of
stay on the ICU and length of stay in the hospital (Table 3
and Additional file 3). Contrarily, NT-proBNP was notFigure 2 Kaplan-Meier survival plots for tertiles of fibroblast growth
factor 23 during long-term follow-up. FGF23, Fibroblast growth factor 23.significantly associated with time of hypothermic circula-
tory arrest, ventilation time or ICU length of stay.
Preoperative measurement of FGF23 and patient risk
assessment
Because FGF23 levels predict short- and long-term post-
operative outcome in patients undergoing elective cardiac
surgery, a single FGF23 measurement could be helpful in
individual preoperative risk assessment. For this purpose,
we analysed multivariable adjusted hazard ratios for the
endpoints mortality, AKI, NOMI and long-term outcome
according to preoperative FGF23 level (Figure 3A to D).
The individual relative risk for acute mortality, AKI, NOMI
or mortality during follow-up according to the individual
preoperative FGF23 level can be easily depicted by com-
parison with the median preoperative FGF23 level of 64
RU/ml (hazard ratio = 1.0).
Discussion
In this large, prospective cohort study, we demonstrate
the strong predictive power of a single preoperative
FGF23 measurement for in-hospital complications and
mortality, as well as for long-term outcome, in patients
undergoing elective cardiac surgery.
FGF23 and postoperative mortality
Preoperative serum FGF23 serum level predicts postop-
erative mortality at least as well as EuroSCORE II. The
EuroSCORE I was developed in 1999 to predict early
mortality in patients undergoing cardiac surgery based
on patient, cardiological and operation-related factors
[7]. Because the mortality associated with cardiac sur-
gery has decreased significantly over the past 15 years,
EuroSCORE II was introduced, incorporating additional
factors proven to influence risk of mortality [6]. Despite
such important modifications, the predictive capacity of
EuroSCORE II for mortality was not superior to a single
preoperative FGF23 measurement. Thus, on the basis of
our present study, we report the novel finding of pre-
operative FGF23 level as a strong predictor of mortality
in patients undergoing cardiac surgery.
FGF23 as a long-term predictive marker
We found a clear association between FGF23 levels and
mortality during the follow-up period. This finding con-
firms former studies, including the ‘Heart and Soul Study’,
which demonstrated an association between FGF23 and
outcomes in non-CKD patients with prevalent coronary
heart disease [24], and the Uppsala Longitudinal Study of
Adult Men, in which FGF23 was independently associated
with elevated cardiovascular mortality during a median
follow-up time of 9.7 years [25].
Although the relationship between FGF23, increased
mortality and cardiovascular disease is well established
Table 2 Cox and logistic regression analyses for FGF23 tertiles and mortality during follow-up, postoperative acute
kidney injury and non-occlusive mesenteric ischaemiaa
Model FGF23 Mortality AKIb NOMIc
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Crude Tertile 1 1 – 1 – 1 –
Tertile 2 1.86 (0.82 to 4.21) 0.137 2.23 (1.42 to 3.51) <0.001 1.83 (0.85 to 3.92) 0.121
Tertile 3 4.40 (2.11 to 9.18) <0.001 6.26 (4.08 to 9.59) <0.001 4.79 (2.42 to 9.48) <0.001
Adjusted model 1d Tertile 1 1 – 1 – 1 –
Tertile 2 1.46 (0.64 to 3.36) 0.370 1.94 (1.21 to 3.10) 0.006 1.53 (0.71 to 3.32) 0.281
Tertile 3 3.05 (1.42 to 6.55) 0.004 4.89 (3.09 to 7.72) <0.001 3.44 (1.69 to 7.02) 0.001
Adjusted model 2e Tertile 1 1 – 1 – 1 –
Tertile 2 1.35 (0.59 to 3.11) 0.482 1.65 (1.01 to 2.67) 0.044 1.24 (0.56 to 2.75) 0.590
Tertile 3 2.34 (1.07 to 5.29) 0.034 2.69 (1.62 to 4.47) <0.001 2.76 (1.30 to 5.85) 0.008
Adjusted model 3f Tertile 1 1 – 1 – 1 –
Tertile 2 1.88 (0.83 to 4.25) 0.131 1.96 (1.24 to 3.10) 0.004 1.59 (0.74 to 3.42) 0.239
Tertile 3 4.54 (2.18 to 9.45) <0.001 4.67 (3.00 to 7.27) <0.001 3.71 (1.84 to 7.48) <0.001
aAKI, Acute kidney injury; CI, Confidence interval; FGF23, Fibroblast growth factor 23; HR, Hazard ratio; NOMI, Non-occlusive mesenteric ischaemia; RU, Relative
units. FGF23 tertile 1: ≤50.6 RU/ml, tertile 2: 50.7 to 89.9 RU/ml, tertile 3: ≥90 RU/ml. bc-Statistics for the prediction of AKI in adjusted model 3: 0.690. cc-Statistics
for the prediction of NOMI in adjusted model 3: 0.590. dAdjusted for age and sex. eAdjusted for age, sex, mean arterial blood pressure, sinus rhythm, coronary
artery disease, chronic heart failure, diabetes, serum creatinine and serum high-sensitivity C-reactive protein. fAdjusted for EuroSCORE II, comprising 18 variables
as described in the Methods section.
Table 3 Linear regression analyses for tertiles of FGF23 and N-terminal fragment of the prohormone B-type brain
natriuretic peptide with different outcome measuresa
FGF23 NT-proBNP
Dependent variable Tertile β (95% CI) P-value β (95% CI) P-value
Duration of surgery Tertile 1 Reference
Tertile 2 12.5 (3.5 to 21.6) 0.007 11.2 (0.6 to 21.7) 0.038
Tertile 3 20.7 (10.6 to 30.8) <0.001 27.9 (16.0 to 39.9) <0.001
Duration of cardiopulmonary bypass Tertile 1 Reference
Tertile 2 6.5 (−0.2 to 12.9) 0.057 4.6 (−2.7 to 12.0) 0.215
Tertile 3 16.2 (8.9 to 23.4) <0.001 22.1 (13.8 to 30.4) <0.001
Time of hypothermic circulatory arrest Tertile 1 Reference
Tertile 2 0.4 (−0.5 to 1.2) 0.441 −0.7 (−1.8 to 0.4) 0.241
Tertile 3 2.0 (1.0 to 3.0) <0.001 0.3 (−0.9 to 1.6) 0.600
Ventilation time Tertile 1 Reference
Tertile 2 2.3 (−12.3 to 16.8) 0.761 −9.6 (−22.7 to 3.5) 0.149
Tertile 3 24.8 (8.6 to 40.9) 0.003 6.6 (−8.2-21.3) 0.384
Length of ICU stay Tertile 1 Reference
Tertile 2 0.2 (−0.5 to 0.9) 0.550 −0.5 (−1.2 to 0.2) 0.166
Tertile 3 1.3 (0.5 to 2.1) 0.001 0.3 (−0.5 to 1.1) 0.444
Total length of stay Tertile 1 Reference
Tertile 2 0.6 (−0.7 to 1.8) 0.365 0.9 (−0.3 to 2.1) 0.133
Tertile 3 1.8 (0.4 to 3.1) 0.009 2.0 (0.6 to 3.3) 0.005
aCI, Confidence interval; FGF23, Fibroblast growth factor 23; ICU, Intensive care unit; NT-proBNP, N-terminal fragment of the prohormone B-type brain natriuretic
peptide; RU, Relative units. Data are adjusted for age, sex, mean arterial blood pressure, sinus rhythm, coronary artery disease, chronic heart failure, diabetes,
serum creatinine and serum high-sensitivity C-reactive protein. Other models for FGF23 are shown in Additional file 3. For FGF23, tertile 1: ≤50.6 RU/ml, tertile 2:
50.7 to 89.9 RU/ml, tertile 3: ≥90 RU/ml; for NT-proBNP, tertile 1: ≤222 pg/ml, tertile 2: 223 to 1,058 pg/ml, tertile 3: ≥1,059 pg/ml.
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Figure 3 Plot of multivariable adjusted hazard ratios according to preoperative levels of fibroblast growth factor 23. (A) Mortality during follow-up.
(B) Acute kidney injury. (C) Non-occlusive mesenteric ischaemia (NOMI). (D) In-hospital mortality. Solid lines represent the hazard ratios (HRs), and
dashed lines the respective 95% confidence intervals. The median of fibroblast growth factor 23 (FGF23) (64 relative units (RU)/ml) was chosen as the
reference value (HR =1). Data are adjusted for age, sex, mean arterial blood pressure, sinus rhythm, coronary artery disease, chronic heart failure,
diabetes, serum creatinine and serum high-sensitivity C-reactive protein. Green areas represent the range of FGF23 with a HR <1, yellow areas with
HR ≥1 and <1.5 and red areas with HR ≥1.5.
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the underlying pathophysiological mechanisms remain
poorly understood. This association of FGF23 and in-
creased mortality and cardiovascular disease was previ-
ously described as being independent of renal function
and increased phosphate intake [26], as well as of trad-
itional risk factors for cardiovascular events (age, obesity,
hypertension, smoking and dyslipidaemia) [24,26,28,29].
Taken together, FGF23 has an undeniable capacity to
predict long-term outcome; however, it remains unclear
whether this is independent of factors linked to cardio-
vascular disease risk or renal function.
FGF23 and acute kidney injury
AKI is a common complication after cardiac surgery
[30-32], with a prevalence of up to 30%. FGF23 is a well-established biomarker for progression in patients with
diabetic and non-diabetic CKD [15,33]. However, FGF23
has only recently been proposed as a potential predictor
of AKI irrespective of preexisting CKD [34]. Our results
clearly reveal preoperative FGF23 level as a strong and
independent predictor of AKI in a large cohort of pa-
tients undergoing elective cardiac surgery.
FGF23 and non-occlusive mesenteric ischaemia
NOMI is a rare but serious complication diagnosed by
angiography after cardiac surgery [22,35,36]. Altered intes-
tinal microcirculation could result from surgical interven-
tion, postoperative cardiorespiratory support, vasopressor
use or potentially the manifestation of a separate disease
process [37-39]. During the observation period, 9% of the
patients in our study population developed NOMI. The
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number of patients with advanced cardiac failure [21,40]
and by the fact that clinically suspected NOMI was con-
firmed by intestinal angiography [21,22].
Preoperative FGF23 level was associated with an in-
creased risk of developing NOMI. Importantly, FGF23
remained an independent predictor of NOMI even after
statistical adjustment for known risk factors in the devel-
opment of postsurgical mesenteric ischaemia. Because
increased FGF23 levels have been linked to impaired
endothelium-dependent vasodilatation in CKD [41], a
similar pathophysiological mechanism could account for
the association between FGF23 and NOMI. Further-
more, FGF23 has been linked to the process of vascular
calcification [20,42], and these patients could be at higher
risk of developing NOMI than patients without vascular
calcification. When these factors are taken together, FGF23
may be deemed a potent predictive marker for vascular
vulnerability in different organs.
FGF23 and cardiac function
Although high levels of FGF23 seem to be associated
with impaired LV function [18,19,43], preexisting cardiac
failure and preoperative cardiac ejection fraction did not
differ between FGF23 tertiles. Furthermore, regression
analyses adjusted for mean arterial blood pressure, car-
diac rhythm, coronary artery disease and congestive car-
diac failure did not significantly impact the prognostic
power of FGF23. This disagreement with previous find-
ings [18,19,43] may be accounted for by differences in
study populations. Cardiac function with regard to LV
ejection fraction or preexisting cardiac failure was gener-
ally lower in our population compared with data re-
ported by Seiler and colleagues [19]. Accordingly, at
baseline, both serum NT-proBNP levels (525 pg/ml ver-
sus 220 pg/ml, respectively) and median plasma FGF23
(64.5 RU/ml versus 38.6 RU/ml, respectively) were
higher in our cohort compared with the cohort studied
by Seiler et al. Although we were unable to confirm an
association between FGF23 and impaired cardiac func-
tion, we observed a significant association between
FGF23 and atrial fibrillation, as Seiler et al. recently re-
ported [19].
Faul and colleagues revealed a Klotho-independent
causal role for FGF23 in the pathogenesis of LV hyper-
trophy [43]. Seiler and colleagues noted a highly significant
and independent association between LV hypertrophy and
function within their study population [19]. However, in
patients with X-linked hypophosphatemia, a rare disease
of primary FGF23 excess [44], data on cardiac structure
are inconsistent with respect to the development of LV
hypertrophy [43,45]. Further studies are required to clarify
any potential association between FGF23 and LV function
independent of LV hypertrophy.FGF23 as predictive marker beyond cardiac and renal
function
Previous studies have shown increased FGF23 levels to
be independently associated with mortality in patients
with CKD [17] and patients undergoing dialysis [16].
Moreover, several studies have shown FGF23 to be a sig-
nificant predictor of cardiovascular outcome independ-
ent of abnormalities of renal function [19,24,33] or
mineral metabolism [46]. Interestingly, our data suggest
that this predictive power is not limited to cardiac or
renal disease. Preoperative FGF23 levels were an inde-
pendent predictor of duration of surgery, duration of
cardiorespiratory support and the time of hypothermic
circulatory arrest. It is possible that by predicting duration
of surgery and time of hypothermic circulatory arrest,
FGF23 may indirectly predict duration of postoperative
cardiorespiratory support. Even after adjusting for preex-
isting cardiac or renal dysfunction, FGF23 remained a sig-
nificant and independent predictor of duration of surgery,
duration of cardiorespiratory support and the time of
hypothermic circulatory arrest. Furthermore, FGF23 inde-
pendently predicted clinical course parameters such as
ventilation time, duration of intensive care and total hos-
pital stay. This may at least in part be explained by its pre-
dictive capacity for severe postoperative complications
such as AKI and NOMI. Notably, FGF23 outperformed
NT-proBNP as a predictor of in-hospital mortality, occur-
rence of AKI and NOMI and mortality postdischarge, as
well as of clinical course parameters, underscoring the
applicability of FGF23 as a general predictor for risk asso-
ciated with cardiac surgery. Moreover, the costs of meas-
uring FGF23 are comparable to those required to measure
NT-proBNP.
Limitations
Despite a numerically large study cohort, the majority of
participants were of Caucasian ancestry, with data ob-
tained within a single tertiary medical centre. Further
multicentre studies are necessary to corroborate the
present findings and to assess their significance and ap-
plicability within a primary care setting. The data pre-
sented are representative only of patients admitted for
elective cardiac surgery. Patients requiring emergency
cardiac surgery were excluded for practical reasons to
avoid ethical issues (that is, informed consent) by a
priori study design. Further studies are necessary to
evaluate whether these findings could be expanded to
patients admitted for emergency cardiac surgery.
Conclusions
A single measurement of serum FGF23 is a powerful
prognostic tool to predict complications, mortality and
clinical course in patients undergoing cardiac surgery.
Because patient selection is the primary means of
Speer et al. Critical Care  (2015) 19:190 Page 9 of 10positively influencing clinical outcome, especially in eld-
erly patients [5], serum FGF23 may aid such clinical selec-
tion. In comparison to the well-established EuroSCORE II
calculation comprising 18 distinct variables, a single
measurement of serum FGF23 is equally effective in pre-
dicting outcome and allows for convenient and simple
risk assessment. Moreover, FGF23 measurements could
offer the possibility for screening risk prior to admission
within a primary care setting, offering major potential
cost benefits.
Key messages
 Fibroblast growth factor 23 (FGF23) is a hormone
which increases renal phosphate excretion. Elevated
levels of FGF23 were described primarily in the
context of impaired renal function and as being
associated with worse clinical outcomes in patients
with cardiac and/or chronic kidney disease.
 Preoperatively determined serum levels of FGF23
seem helpful in assessing the risk for postoperative
complications, including acute renal failure and
mortality, in patients undergoing elective cardiac
surgery.
 In patients undergoing elective cardiac surgery, a
simple preoperative FGF23 measurement is a
powerful indicator of surgical mortality,
postoperative complications, and long-term
outcome. Its utility compares well with the widely
used EuroSCORE II comprising 18 distinct variables,
and it outperforms NT-proBNP.
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